JFG
ELTX icon

Jefferies Financial Group’s Elicio Therapeutics ELTX Stock Holding History

Jefferies Financial Group’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,942
Closed -$95.1K – 1868
2025
Q4 		$95.1K Buy
11,942
+6,742
+130% +$61.2K ﹤0.01% 1711
2025
Q3 		$56.9K Buy
+5,200
New +$52.6K ﹤0.01% 1381

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Financial Group's ELTX Position: Q1 2026 in Review

Jefferies Financial Group sold out of Elicio Therapeutics (ELTX) in Q1 2026, closing a stake of 11,942 shares — an estimated $95.1K sold.

Jefferies Financial Group first reported a position in ELTX in Q3 2025 and held it in 2 quarters. The position peaked at $95.1K in Q4 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Jefferies Financial Group reported no remaining Elicio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 11,942 Elicio Therapeutics shares in Q1 2026, an estimated $95.1K.
  • Jefferies Financial Group first reported a position in Elicio Therapeutics in Q3 2025 and held it in 2 quarters.
  • Jefferies Financial Group's Elicio Therapeutics position peaked at $95.1K in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.